5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC

Key Points

• Legacy Edge Advisors established a new position in AbbVie, buying 5,538 shares in Q4 valued at about $1.27 million, according to the firm's latest 13F filing.
• AbbVie beat Q1 estimates and raised its 2026 outlook as immunology drugs (Skyrizi, Rinvoq) help offset Humira declines, prompting multiple analyst upgrades and a consensus rating of "Moderate Buy" with an average price target of $252.90.
• There was notable insider selling (SVP sold 5,230 shares; EVP sold 22,381 shares), while the company announced a quarterly dividend of $1.73 per share (3.3% yield) despite a very high payout ratio (~341%).

Legacy Edge Advisors LLC bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,538 shares of the company's stock, valued at approximately $1,265,000.

A number of other hedge funds also recently bought and sold shares of the company. Chelsea Counsel Co. purchased a new position in AbbVie in the 3rd quarter worth approximately $26,000. Westend Capital Management LLC purchased a new position in AbbVie in the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie in the 3rd quarter worth approximately $31,000. WestEnd Advisors LLC increased its stake in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after purchasing an additional 85 shares during the period. Finally, Caitlin John LLC purchased a new position in AbbVie in the 3rd quarter worth approximately $33,000. Institutional investors own 70.23% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ABBV shares. Piper Sandler decreased their price target on AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research note on Thursday, April 23rd. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Canaccord Genuity Group lifted their price target on AbbVie from $262.00 to $265.00 and gave the stock a "buy" rating in a research note on Thursday. Royal Bank Of Canada started coverage on AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target on the stock. Finally, UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research note on Thursday, February 5th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and an average price target of $252.90.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by insiders.

AbbVie Stock Performance

ABBV opened at $206.63 on Friday. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The stock has a market capitalization of $365.36 billion, a PE ratio of 101.79, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32. The stock's 50 day moving average price is $214.55 and its 200-day moving average price is $221.54.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analysts' expectations of $14.72 billion. During the same period in the previous year, the firm earned $2.46 earnings per share. The business's revenue was up 12.4% compared to the same quarter last year. Research analysts forecast that AbbVie Inc. will post 14.29 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie's payout ratio is 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.